In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Organon (OGN – Research Report), with a price target of $24.00. The company’s shares closed last Friday at $18.55.
Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Ironwood Pharma, and Supernus Pharmaceuticals. According to TipRanks, Amsellem has an average return of -3.3% and a 40.56% success rate on recommended stocks.
In addition to Piper Sandler, Organon also received a Buy from Barclays’s Balaji Prasad in a report issued on April 23. However, on April 19, Goldman Sachs maintained a Hold rating on Organon (NYSE: OGN).
Based on Organon’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.6 billion and a net profit of $546 million. In comparison, last year the company earned a revenue of $1.49 billion and had a net profit of $108 million
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organon (OGN) Company Description:
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women’s health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
